Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
NGNE
$19.7681
$
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Next Earnings
2026-02-25
Beta
2.041
Average Volume
Market Cap
Last Dividend
CIK
0001404644
ISIN
US64135M1053
CUSIP
64135M105
CEO
Rachel L. McMinn
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
107
IPO Date
2014-03-07
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Neurogene Inc. (NASDAQ:NGNE) Receives $44.00 Average Price Target from Analysts | Shares of Neurogene Inc. (NASDAQ: NGNE - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the | Defense World | 2026-02-16 01:58:52 |
| Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit | Neurogene (NASDAQ: NGNE) is advancing a genetic medicines pipeline focused on rare neurologic diseases, with its lead program NGN-401 aimed at treating Rett syndrome, President and CFO Christine Mikail said at Guggenheim's 2026 Emerging Outlook Biotech Summit. Mikail described Rett syndrome as a "devastating neurologic disease" that primarily affects girls. She said children often show developmental | Defense World | 2026-02-16 01:02:54 |
| Neurogene to Participate in Upcoming Investor Conferences | NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences: Guggenheim Emerging Outlook: Biotech Summit 2026 Format: Management will participate in a fireside chat and investor meetings Date: Thursday, February 12 at 9:00 a.m. ET TD Cowen 46th Annual Health Care Conference F. | Business Wire | 2026-02-05 07:30:00 |
| Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,820 shares of the Company's common stock to one new employee (the “Inducement Grant”) on February 2, 2026 (the “Grant Date”). The Induceme. | Business Wire | 2026-02-04 16:01:00 |
| Analysts Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $42.50 | Neurogene Inc. (NASDAQ: NGNE - Get Free Report) has received a consensus rating of "Moderate Buy" from the six brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year | Defense World | 2026-01-22 01:31:05 |
| Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome | NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today provided an update on recent achievements for NGN-401 gene therapy for the treatment of Rett syndrome and plans for multiple value-creating catalysts anticipated in 2026. “We are pleased to share that multiple participants have been dosed in our Embolden registrational trial of NGN-401 gene ther. | Business Wire | 2026-01-12 07:00:00 |
| Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference | NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the 44th Annual J.P. Morgan Healthcare Conference. Format: Management will present a company overview and participate in investor meetings Date: Wednesday, January 14 at 7:30 a.m. PT A webcast of the presentation will be accessible from the I. | Business Wire | 2026-01-05 07:30:00 |
| Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 4,860 shares of the Company's common stock to two new employees (the “Inducement Grants”) on December 2, 2025 (the “Grant Date”). The Induce. | Business Wire | 2025-12-04 16:01:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| SC 13G | 2025-12-15 | 2025-12-15 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-06 | 2025-11-06 | View Filing |
| 8-K | 2025-10-09 | 2025-10-09 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 424B5 | 2025-08-11 | 2025-08-11 | View Filing |
| 8-K | 2025-08-11 | 2025-08-11 | View Filing |
| 10-Q | 2025-08-11 | 2025-08-11 | View Filing |
| 8-K | 2025-06-30 | 2025-06-30 | View Filing |
| 4 | 2025-06-13 | 2025-06-13 | View Filing |
| 4 | 2025-06-13 | 2025-06-13 | View Filing |
| 4 | 2025-06-13 | 2025-06-13 | View Filing |
| 4 | 2025-06-13 | 2025-06-13 | View Filing |
| 4 | 2025-06-13 | 2025-06-13 | View Filing |
| 8-K | 2025-06-12 | 2025-06-12 | View Filing |
| 8-K | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-12 | 2025-05-12 | View Filing |
| 8-K | 2025-05-09 | 2025-05-09 | View Filing |
| 10-Q | 2025-05-09 | 2025-05-09 | View Filing |
| ARS | 2025-04-25 | 2025-04-25 | View Filing |
| DEFA14A | 2025-04-25 | 2025-04-25 | View Filing |
| DEF 14A | 2025-04-25 | 2025-04-25 | View Filing |
| SC 13G/A | 2025-04-23 | 2025-04-23 | View Filing |
| 8-K | 2025-04-14 | 2025-04-14 | View Filing |
| EFFECT | 2025-04-07 | 2025-04-07 | View Filing |
| 424B3 | 2025-04-01 | 2025-04-01 | View Filing |
| EFFECT | 2025-03-31 | 2025-03-31 | View Filing |
| 4 | 2025-03-28 | 2025-03-28 | View Filing |
| 4 | 2025-03-28 | 2025-03-28 | View Filing |
| 4 | 2025-03-28 | 2025-03-28 | View Filing |
| 4 | 2025-03-28 | 2025-03-28 | View Filing |
| S-3 | 2025-03-24 | 2025-03-24 | View Filing |
| POS AM | 2025-03-24 | 2025-03-24 | View Filing |
| S-8 | 2025-03-24 | 2025-03-24 | View Filing |
| 8-K | 2025-03-24 | 2025-03-24 | View Filing |
| 10-K | 2025-03-24 | 2025-03-24 | View Filing |
| 4 | 2025-03-17 | 2025-03-17 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| 8-K | 2025-01-13 | 2025-01-13 | View Filing |
| 424B3 | 2024-12-18 | 2024-12-18 | View Filing |
| EFFECT | 2024-12-17 | 2024-12-17 | View Filing |
| SC 13G | 2024-12-11 | 2024-12-11 | View Filing |
| S-1 | 2024-12-02 | 2024-12-02 | View Filing |
| 4 | 2024-11-27 | 2024-11-27 | View Filing |
| 3 | 2024-11-27 | 2024-11-27 | View Filing |
| SC 13G/A | 2024-11-27 | 2024-11-27 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 8-K | 2024-11-21 | 2024-11-21 | View Filing |
| 10-Q | 2024-11-18 | 2024-11-18 | View Filing |
| 8-K | 2024-11-18 | 2024-11-18 | View Filing |
| 8-K | 2024-11-18 | 2024-11-18 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| NT 10-Q | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G | 2024-11-08 | 2024-11-08 | View Filing |
| 8-K | 2024-11-04 | 2024-11-04 | View Filing |
| 10-Q | 2024-08-09 | 2024-08-09 | View Filing |
| 8-K | 2024-08-09 | 2024-08-09 | View Filing |
| 8-K | 2024-08-07 | 2024-08-07 | View Filing |
| SC 13G | 2024-07-08 | 2024-07-08 | View Filing |
| 8-K | 2024-06-21 | 2024-06-21 | View Filing |
| 8-K | 2024-06-18 | 2024-06-18 | View Filing |
| 4 | 2024-06-17 | 2024-06-17 | View Filing |
| 4 | 2024-06-17 | 2024-06-17 | View Filing |
| 4 | 2024-06-17 | 2024-06-17 | View Filing |
| 4 | 2024-06-17 | 2024-06-17 | View Filing |
| 4 | 2024-06-17 | 2024-06-17 | View Filing |
| 8-K | 2024-06-17 | 2024-06-17 | View Filing |
| 8-K | 2024-06-03 | 2024-06-03 | View Filing |
| 10-Q | 2024-05-10 | 2024-05-10 | View Filing |
| 8-K | 2024-05-10 | 2024-05-10 | View Filing |
| 8-K | 2024-05-07 | 2024-05-07 | View Filing |
| DEFA14A | 2024-04-26 | 2024-04-26 | View Filing |
| ARS | 2024-04-26 | 2024-04-26 | View Filing |
| DEF 14A | 2024-04-26 | 2024-04-26 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Liquidity Sweep Strategy | 8,546.14% | 0.67 | 10 | 0.41 | 87.86 | 6404.92 |
| Choppiness Index Strategy | 2,141.21% | 0.89 | 29 | 0.4 | 10.2 | 0 |
| Donchian Channel Strategy | 2,141.21% | 0.77 | 19 | 0.4 | 9.74 | 0 |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxx | xxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | x | xxxx |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxx% | x | x | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | x | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xx% | xxx | xx | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | xxxx | x | x | x | xxxxxxx |
| xxxxxxxxx | x% | x | x | x | x | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |